Benefit risk considerations for African swine fever virus live attenuated vaccines
In response to the recent publication on safety concerns related to “ASFV-G-∆I177L” by van den Born et al. (2025), we emphasize the need for a thorough, context-specific risk assessment before drawing conclusions about the general field use of the ASFV-G-∆I177L vaccine strain. While valid safety con...
Saved in:
| Main Authors: | Sandra Blome, Virginia Friedrichs, Alexander Schäfer, Martin Beer |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-025-01208-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Maternal immunity and African swine fever virus: understanding the limits of passive protection
by: Virginia Friedrichs, et al.
Published: (2025-07-01) -
Attenuated African swine fever viruses and the live vaccine candidates: a comprehensive review
by: Jiaqi Fan, et al.
Published: (2024-11-01) -
Editorial: Basic and applied research toward the development of vaccines against African swine fever virus
by: Daniel Pérez-Núñez, et al.
Published: (2025-08-01) -
African swine fever virus – variants on the rise
by: Jan H. Forth, et al.
Published: (2023-12-01) -
African Swine Fever in Saxony—Disease Dynamics
by: Katja Schulz, et al.
Published: (2024-12-01)